In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
The majority of oncology therapeutics are in the early stages of the pipeline, with 2,937 (45%) at the preclinical stage and 1,591 (25%) at the discovery stage. 3 December 2015
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). 2 December 2015
Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics for the treatment of multiple myeloma and other cancers, has closed a £19.0 million ($28.6 million) Series A funding round from a syndicate of leading venture investors including Innovations, SV Life Sciences and Abingworth. 2 December 2015
Cellceutix Corp revealed that the US Food and Drug Administration has granted Rare Pediatric Disease designation for its Kevetrin (thioureidobutyronitrile) for the treatment of retinoblastoma. 2 December 2015
USA-based Lexicon Pharmaceuticals says that top-line data from its TELECAST Phase III study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study. 1 December 2015
Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group said mid-stage trials for its WT1 cancer vaccine have shown clinically meaningful prolonged survival. 1 December 2015
The US Food and Drug Administration granted approval today for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. 30 November 2015
Cheaper generic drugs may soon be commonplace in India with the government aiming to sell around 400 medications at lower prices by this December, through its Jan Aushadhi stores. 30 November 2015
Switzerland-based cancer specialist Helsinn Group on Monday said the European Medicines Agency has agreed to review marketing authorization application (MAA) for its anamorelin HCI, to treat anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients. 30 November 2015
The US Food and Drug Administration on Friday declined to approve expanded use of Pharma major Bristol-Myers Squibb’s Opdivo (nivolumab) based on current data. 28 November 2015
Roche has prevailed in a patent challenge law suit against Indian drug major Cipla, with the Delhi High Court today holding that the company was infringing Roche's patent on lung cancer drug erlotinib hydrochloride, sold under the trade name Tarceva, reports the Business Standard and other local media. 27 November 2015
Swiss drug company Roche has said the European Union has given its nod of approval for the company’s Cotellic (cobimetinib) for use in combination with the drug Zelboraf (vemurafenib) to treat advanced melanoma. 26 November 2015
US biotech firm Celgene Corp’s Otezla (apremilast) to treat chronic plaque psoriasis, has been dropped from the list of recommendations by the National Institute for Health and Care Excellence (NICE). 26 November 2015
The European Medicine’s Agency’s (EMA) committee for orphan medicinal products (COMP) has issued a positive opinion backing Orphan Drug Designation (ODD) for avelumab, it has been announced. 25 November 2015
The US Food and Drug Administration yesterday approved pharma major Eli Lilly’s Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. 25 November 2015
Solasia Pharma has entered into an exclusive license agreement with Hong Kong-based Lee’s Pharmaceutical for the commercialization and promotion of Sancuso (granisetron transdermal delivery system) in the People’s Republic of China. 25 November 2015
Denmark’s Genmab revealed yesterday that the Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin’s lymphoma (NHL) that has relapsed at least six months after completion of treatment with a rituximab-containing regimen will be stopped early. 24 November 2015
The US Food and Drug Administration yesterday approved US pharma major Bristol-Myers Squibb’s Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma. 24 November 2015
US pharmaceutical company Bristol-Myers Squibb has announced positive results from a Phase III study of Opdivo (nivolumab) in advanced, treatment-naive melanoma patient 24 November 2015